Causes of mortality to day 300, reduced-intensity allografts
| . | Reduced-intensity conditioning . | ||
|---|---|---|---|
| Sibling . | VUD . | All . | |
| Days 0 to 100 | Total = 6, TRM = 2 | Total = 5, TRM = 4 | Total = 11, TRM = 6 |
| Relapse/progressive disease | 4 | 1 | 5 |
| Primary graft failure* | 0 | 1 | 1 |
| Parainfluenza III pneumonitis* | 1 | 0 | 1 |
| Bacterial sepsis* | 1 | 2 | 3 |
| Perforated viscus* | 0 | 1 | 1 |
| Days 101 to 200 | Total = 4, TRM = 1 | Total = 7, TRM = 6 | Total = 11, TRM = 7 |
| Relapse | 3 | 1 | 4 |
| Thrombotic thrombocytopenic | 1 | 0 | 1 |
| purpura* | 0 | 1 | 1 |
| Bacterial bronchopneumonia* | 0 | 1 | 1 |
| PTLD* | 0 | 1 | 1 |
| CMV pneumonitis* | 0 | 1 | 1 |
| Adenovirus infection* | 0 | 1 | 1 |
| Parainfluenza III pneumonitis* | 0 | 1 | 1 |
| Late graft failure* | |||
| Days 201 to 300 | Total = 2, TRM = 1 | Total = 2, TRM = 1 | Total = 4, TRM = 1 |
| Relapse | 1 | 1 | 2 |
| RSV pneumonitis* | 0 | 1 | 1 |
| Bacterial pneumonia* | 1 | 0 | 1 |
| . | Reduced-intensity conditioning . | ||
|---|---|---|---|
| Sibling . | VUD . | All . | |
| Days 0 to 100 | Total = 6, TRM = 2 | Total = 5, TRM = 4 | Total = 11, TRM = 6 |
| Relapse/progressive disease | 4 | 1 | 5 |
| Primary graft failure* | 0 | 1 | 1 |
| Parainfluenza III pneumonitis* | 1 | 0 | 1 |
| Bacterial sepsis* | 1 | 2 | 3 |
| Perforated viscus* | 0 | 1 | 1 |
| Days 101 to 200 | Total = 4, TRM = 1 | Total = 7, TRM = 6 | Total = 11, TRM = 7 |
| Relapse | 3 | 1 | 4 |
| Thrombotic thrombocytopenic | 1 | 0 | 1 |
| purpura* | 0 | 1 | 1 |
| Bacterial bronchopneumonia* | 0 | 1 | 1 |
| PTLD* | 0 | 1 | 1 |
| CMV pneumonitis* | 0 | 1 | 1 |
| Adenovirus infection* | 0 | 1 | 1 |
| Parainfluenza III pneumonitis* | 0 | 1 | 1 |
| Late graft failure* | |||
| Days 201 to 300 | Total = 2, TRM = 1 | Total = 2, TRM = 1 | Total = 4, TRM = 1 |
| Relapse | 1 | 1 | 2 |
| RSV pneumonitis* | 0 | 1 | 1 |
| Bacterial pneumonia* | 1 | 0 | 1 |
There were no deaths attributable to GVHD.
PTLD indicates posttransplantation lymphoproliferative disorder; and VOD, veno-occlusive disease.
Indicates TRM.